Form 8-K - Current report:
SEC Accession No. 0001493152-24-036453
Filing Date
2024-09-16
Accepted
2024-09-16 17:29:54
Documents
17
Period of Report
2024-09-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 47348
2 ex1-1.htm EX-1.1 294037
3 ex5-1.htm EX-5.1 11417
4 ex5-1_001.jpg GRAPHIC 39694
5 ex5-1_002.jpg GRAPHIC 38047
  Complete submission text file 0001493152-24-036453.txt   710806

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE zvsa-20240916.xsd EX-101.SCH 3012
7 XBRL LABEL FILE zvsa-20240916_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE zvsa-20240916_pre.xml EX-101.PRE 24163
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3815
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41184 | Film No.: 241302031
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)